Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine versus lithium monotherapy for newly diagnosed bipolar II disorder
ACTRN12616001702404Phase 3Terminated
- Sponsor
- Professor Gordon Parker
- Start
- Mar 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of lamotrigine and lithium carbonate in Bipolar II disorder (BP-II), sponsored by Professor Gordon Parker. Started Mar 2017; status: terminated.
02
Drugs
lamotriginelithium carbonate
03
Conditions
Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on ACTRN12616001702404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001702404.